Format

Send to

Choose Destination
Indian J Surg Oncol. 2016 Jun;7(2):160-5. doi: 10.1007/s13193-016-0500-x. Epub 2016 Feb 2.

The Initial Indian Experience with Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases.

Author information

1
Department of Surgical Oncology, Fortis Hospital, 154/9 Bannerghatta road, Opposite IIM-Bangalore, Bangalore, -560076 India.
2
Department of Surgical Oncology, Saifee Hospital, Mumbai, India.
3
Department of Surgical Oncology, Cancer Institute (WIA), Chennai, India.
4
Department of General Sugery, Sion Hospital Mumbai, Mumbai, India.
5
Department of Surgical Oncology, Manipal Hospital, Bangalore, India.
6
Department of Surgical Oncology, Kovai Medical Centre, Coimbatore, India.
7
Department of Surgical Oncology, Apollo Hospital, Chennai, India.
8
Department of GI Oncology, Rajiv Gandhi Cancer Centre, New Delhi, India.
9
Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC USA.

Abstract

Worldwide, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for nearly 3 decades to treat peritoneal metastases (PM), improve quality of life, and prolong survival substantially in selected patients. In India, the use of the combined modality of treatment dates back a decade with majority of the efforts taking place within the last 5 years. The first PSOGI workshop (India) held in April 2015, at Bangalore, India offered an opportunity for Indian surgeons performing CRS and HIPEC to share their experience. To study the methodologies of CRS and HIPEC (hospital set up, equipment, training and surgical background) as well as the outcomes in terms of perioperative morbidity and mortality and short and long term survival of patients treated in India, Indian surgeons who had treated at least 10 patients with this combined modality were invited to present their experience. Data collection was retrospective. Analysis of the pooled data was carried out. Eight surgeons treated 384 patients with CRS and HIPEC over a period of 10 years. The commonest primary sites were ovary (as first line therapy n = 124), followed by appendix, including pseudomyxoma peritonei (n = 99), colorectum (n = 77), recurrent ovary (as second line therapy, n = 33), stomach (n = 15), primary peritoneal cancer (n = 10), peritoneal mesothelioma (n = 9) and rare tumors in 17 patients. The weighted mean PCI for all 384 patients was 18.25. 349/384 patients (90.88 %) had a complete cytoreduction (completeness of cytoreduction score of CC-0/1). Grade 3-5 complications developed in 108 patients (27.34 %) and 30 day mortality occurred in 28 (7.29 %) patients. This study showed that CRS and HIPEC can be performed with an acceptable morbidity and mortality in Indian patients. Most of the surgeons are on the learning curve and further improvement in these outcomes is expected over a period of time. Pooling of data related to both common and rare peritoneal cancers would be useful in knowing the disease behavior, response to treatment and outcomes in Indian patients. The 2015 PSOGI meeting provided a unique platform for data presentation with feedback from international experts in the field of peritoneal surface oncology. Future meetings are planned to expand the evaluation of Indian data and progress.

KEYWORDS:

Cytoreductive Surgery; HIPEC; Indian Experience; Peritoneal Metastases

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center